X
Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome
https://pharmaphorum.com/news/novos-new-oral-glp-1-still-has-obstacles-to-overcome/
Ozempic
Trulicity helps SGLT-2 patients lower blood sugar
New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.
Novo Nordisk undeterred after losing out on Ablynx takeover
After losing out to Sanofi in its pursuit of Belgian biotech Ablynx earlier this week, Novo Nordisk has put a brave face on the disappointment.